Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study

Bin Su, Yao Cheng, Qingxia Zhao, Weiping Cai, Min Wang, Hongzhou Lu, Tingting Mu, Yuanyuan Chen, Li Liu, Hui Wang, Yun He, Yu-huang Zheng, Linghua Li, Jinfeng Chen, Jianhua Yu, Biao Zhu, Min Zhao, Yongtao Sun, Wenhui Lun, Yihang Zhang, Hu Wang, Wei Xia, Lijun Sun, Lili Dai, Taiyi Jiang, Meixia Wang, Qingshan Zheng, Haiyan Peng, Yao Wang, Min Hu, Xia Liu, Rongjian Lu, Jianhua Hu, Cheng-Chen Sun, Hui Xing, Yiming Shao, Dong Xie, Tong Zhang, Fujie Zhang, Hao Wu